Avicanna Inc. (TSX:AVCN)

Market Cap	20.13M -29.8%
Revenue (ttm)	25.50M +2.4%
Net Income	-1.88M
EPS	-0.02
Shares Out	125.79M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,000
Average Volume	36,681
Open	0.1650
Previous Close	0.1650
Day's Range	0.1600 - 0.1650
52-Week Range	0.1500 - 0.3850
Beta	0.26
RSI	33.29
Earnings Date	Mar 31, 2026

About Avicanna

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of de...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 87
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: AVCN

Financial Performance

In 2024, Avicanna's revenue was 25.46 million, an increase of 51.62% compared to the previous year's 16.79 million. Losses were -3.62 million, -58.62% less than in 2023.